by Steven A. Grossman | Oct 14, 2025 | Short Takes and Updates
The announcement that former CBER Director, Dr. Peter Marks, was joining Lilly as SVP for molecule discovery and head of infectious diseases….set the internet ablaze with unjustified outrage about his transition from a government career to industry. My multiple...
by Steven A. Grossman | Oct 13, 2025 | Uncategorized
This week’s questions:How long is the shutdown likely to continue?Did Commissioner Makary offer companies accelerated review if they make the pricing concessions requested by the Administration?Where does the farm community fit into the MAHA agenda?——Q: How long...
by Steven A. Grossman | Oct 10, 2025 | Short Takes and Updates
Every day, our country is failing patients with relentlessly progressive chronic neurological, neuromuscular, and genetic diseases. Their plight necessitates a significantly different risk-benefit calculation than that of patients with other types of diseases....
by Steven A. Grossman | Oct 6, 2025 | Uncategorized
This week’s questions:State public health officials are having to make difficult decisions about whether to follow CDC guidance on vaccines and other topics. Could there be a similar erosion of trust by states regarding FDA guidance?Anti-vaccine policies poll poorly...
by Steven A. Grossman | Oct 3, 2025 | Short Takes and Updates
Every Monday, FDA Mtters subscribers receive “Q&A Monday.” They may recirculate, quote from, or reprint it, etc., at their own discretion, which can be particularly useful for media. I do not publicly post the column until the following Monday. You can find past...
